Asensus claims its Senhance can do a hysterectomy for half what Intuitive’s DaVinci robot costs, with renewable instruments and haptic feedback. The long haul is the only way to play ASXC stock. Read More
Asensus Surgical Investors Need To Take Long-Term View on Its Technology
2021-05-31T10:00:45-04:00May 31st, 2021|